Nanjing Legend Biotech
Nanjing
China
8 articles with Nanjing Legend Biotech
-
Legend Biotech and J&J, Adicet Bio, Curis and Immutep present optimistic early and mid-stage results at ASCO.
-
The U.S. SEC continues to tighten the screws on Chinese companies, adding more than 80 companies to its expanding list of companies that might be dropped from U.S. stock exchanges.
-
CARVYKTI™ (ciltacabtagene autoleucel), BCMA-Directed CAR-T Therapy, Receives U.S. FDA Approval for the Treatment of Adult Patients With Relapsed or Refractory Multiple Myeloma
3/1/2022
Legend Biotech Corporation announced that the U.S. Food and Drug Administration has approved its first product, CARVYKTI™, for the treatment of adults with relapsed or refractory multiple myeloma who have received four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
-
Clinical Catch-Up: December 11-17
12/20/2021
It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look. -
The U.S. Food and Drug Administration has a very busy calendar for the end of November and beginning of December. Here’s a look.
-
Two months after he was stepped down from the role of chief executive officer of Legend Biotech, Fangliang “Frank” Zhang has been arrested for smuggling genetic resources from the People’s Republic of China.
-
Legend’s CEO and Board Chairman, Fangliang “Frank” Zhange, was placed on “residential surveillance” by PRC law enforcement.
-
Legend Announces FDA clearance of IND application on CAR-T immuno-cell therapy for the Treatment of Multiple Myeloma
5/30/2018
LCAR-B38M CAR-T therapy (JNJ-68284528) to be developed as part of strategic partnership between Legend and Janssen